<DOCUMENT>
<TYPE>EX-10.53
<SEQUENCE>4
<FILENAME>a2106640zex-10_53.htm
<DESCRIPTION>EXHIBIT 10.53
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03SAN1114_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ke1114_exhibit_10.53"> </A>
<A NAME="toc_ke1114_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.53    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>AMENDMENT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment to the Collaborative Research and License Agreement dated July&nbsp;9, 2001, ("Agreement"), by and between </FONT><FONT SIZE=2><B>ISIS
PHARMACEUTICALS,&nbsp;INC.</B></FONT><FONT SIZE=2> ("Isis"), a Delaware corporation, with its principal office at 2292 Faraday Avenue, Carlsbad, California 92008 and </FONT><FONT SIZE=2><B>PE
CORPORATION (NY),</B></FONT><FONT SIZE=2> a New York corporation, through the </FONT><FONT SIZE=2><B>CELERA GENOMICS GROUP</B></FONT><FONT SIZE=2>, ("Celera"), having a principal place of business at
45 West Gude Drive, Rockville, Maryland 20850. Celera and Isis may be referred to herein individually as a "Party" and collectively as the "Parties". </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Celera and Isis entered into the Agreement to collaborate to generate information on gene function for up to 250 gene targets; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Celera and Isis desire to amend the Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the mutual covenants and promises contained herein, the Parties agree to amend the Agreement as follows: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Section&nbsp;1.4(a)
is added as follows: </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>1.4(a)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="78%"><FONT SIZE=2>"Celera Conditional Target" means a Gene selected by Celera and included by Isis in the HTGF queue under the conditions set forth in Section&nbsp;3.1(b).</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Section&nbsp;3.1(b)
is amended by adding the following: </FONT></DD></DL>
</UL>
<UL>
<UL>

<P><FONT SIZE=2>Upon
approval by Celera, Isis will include a Gene in the HTGF queue notwithstanding the right of Isis under this Section to exclude such Gene provided that such Gene will not become: (i)&nbsp;part
of the Celera Gene Availability Pool, or (ii)&nbsp;a Celera Exclusive Target (such Gene a "Celera Conditional Target"). Except as provided in the preceding sentence, all Celera Conditional Targets
will be treated equally hereunder with any other Gene included in the HTGF queue. Isis will notify Celera in writing of the identity of any Gene which Isis would include in the HTGF queue only as a
Celera Conditional Target within ten (10)&nbsp;business days of Celera's selection of such Gene. If Celera wishes to approve such Gene as a Celera Conditional Target, Celera will notify Isis in
writing within fifteen (15)&nbsp;business days of receipt of Isis's notification, provided, however, that Isis will have no obligation to reserve such Gene for Celera prior to receiving notification
of Celera's approval of such Gene as a Celera Conditional Target. If Celera does not approve such Gene as a Celera Conditional Target, such Gene will become a Rejected Gene. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Amendment will be attached to the Agreement and incorporated therein. All other terms of the Agreement will remain in full force and effect. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><B> PE CORPORATION (NY)</B></FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><B>ISIS PHARMACEUTICALS, INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><BR><FONT SIZE=2>By:</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK D. ADAMS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>B. LYNNE PARSHALL</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>Mark D. Adams, Ph.D.<BR>
Vice President, Genome Programs</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>B. Lynne Parshall<BR>
Executive Vice President</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
Date: 4/19/02</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
Date: 4/22/02</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2106640",CP="ISIS PHARMACEUTICALS, INC.",DN="3",CHK=634287,FOLIO='blank',FILE='DISK008:[03SAN4.03SAN1114]KE1114A.;16',USER='JHILL',CD='31-MAR-2003;13:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03SAN1114_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ke1114_1">Exhibit 10.53</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SFLORES,SEQ=,EFW="2106640",CP="ISIS PHARMACEUTICALS, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
